Chaoyang Li is a prominent inventor based in Newbury Park, California. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. With a total of three patents to his name, Li's work has the potential to impact various medical treatments.

Latest Patents

One of Chaoyang Li's latest patents focuses on DKK1 antibodies and methods of use. This invention provides antibodies and immunologically functional fragments that specifically bind to DKK1 polypeptides. The patent also outlines methods for preparing these antibodies or fragments, as well as physiologically acceptable compositions containing them. Furthermore, the use of these antibodies and fragments to treat various diseases is disclosed, showcasing the therapeutic potential of his work.

Career Highlights

Chaoyang Li is currently associated with Amgen Inc., a leading biotechnology company. His role at Amgen allows him to collaborate with other experts in the field and contribute to groundbreaking research and development.

Collaborations

Some of Chaoyang Li's notable coworkers include William Gleason Richards and Hsieng Sen Lu. Their collaboration fosters an environment of innovation and shared expertise, enhancing the potential for impactful discoveries.

Conclusion

Chaoyang Li's contributions to biotechnology, particularly through his patents on DKK1 antibodies, highlight his role as an influential inventor. His work at Amgen Inc. and collaborations with esteemed colleagues further emphasize the importance of innovation in medical science.

Profile summary based on public USPTO records.